AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPublished in a peer-reviewed journal
Risk of Inflammatory Bowel Disease After Rituximab in Individuals with RRMS
A cohort study with 13,748 therapy episodes found that among individuals receiving rituximab, 40 developed inflammatory bowel disease (IBD), compared to only 4 in those receiving other disease-modifying therapies. The incidence rate was 110 per 100,000 person-years for rituximab, significantly higher than for comparator treatments (13 per 100,000).
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Demonstrated in people
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
This study highlights a potential increased risk of IBD with rituximab compared to newer MS treatments, which is important for patient guidance and risk assessment.
What this does not prove
The findings are based on a specific cohort from the Swedish MS register, limiting the generalizability to all individuals with MS.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 13748 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS
- Publication date
- 2026-10-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Individuals with RRMS aged 18 to 55 years
- Size of effect
- 0.10 (95% CI, 0.04-0.22)
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceRisk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis. ↗DOI: 10.1001/jamaneurol.2026.3439
Supporting passages (13)
study designThis was a population-based cohort study conducted in Sweden.
subjectsThrough the Swedish MS register, initiations of rituximab, natalizumab, dimethyl fumarate, and fingolimod were identified between January 1, 2011, and December 31, 2023, in individuals with RRMS aged 18 to 55 years with at least 10 years of lookback time (5 years for dispensed drugs) and no evidence of previous IBD.
sample sizeRESULTS: Among the 13 748 therapy episodes (6481 rituximab, 2976 natalizumab, 2767 dimethyl fumarate, 1524 fingolimod) in 9251 individuals (range in mean ages of the exposure groups, 35-38 years) and 61 065 matched general population episodes, 164 IBD events occurred during follow-up (40 with rituximab, 4 with comparator DMTs, and 120 in the general population).
relevant ms typesRRMS.
interventionIMPORTANCE: Anti-CD20 biologics are widely used as disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), but recent reports have raised concerns about an increased risk of inflammatory bowel disease (IBD) during treatment.
primary endpointMAIN OUTCOMES AND MEASURES: New-onset IBD, defined as 2 or more records on separate dates with the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes K50 (Crohn disease), K51 (ulcerative colitis), and/or K52.3 (indeterminate colitis).
findingsRESULTS: Among the 13 748 therapy episodes (6481 rituximab, 2976 natalizumab, 2767 dimethyl fumarate, 1524 fingolimod) in 9251 individuals (range in mean ages of the exposure groups, 35-38 years) and 61 065 matched general population episodes, 164 IBD events occurred during follow-up (40 with rituximab, 4 with comparator DMTs, and 120 in the general population).
populationThrough the Swedish MS register, initiations of rituximab, natalizumab, dimethyl fumarate, and fingolimod were identified between January 1, 2011, and December 31, 2023, in individuals with RRMS aged 18 to 55 years with at least 10 years of lookback time (5 years for dispensed drugs) and no evidence of previous IBD.
effect sizeAfter adjustment for demographics and MS characteristics, the hazard ratio for the comparator DMTs vs rituximab was 0.10 (95% CI, 0.04-0.22).
human efficacyCONCLUSIONS AND RELEVANCE: Results of this cohort study show that rituximab was associated with an increased risk of IBD compared with other modern MS therapies, after adjustment for differences in characteristics at therapy start.
publication datePublication date: 2026-10-22
limitationsTitle: Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.